Airway Therapeutics

  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact

Airway Therapeutics Announces Appointment of Chief Medical Officer

August 25, 2018 By Airway Therapeutics

(Cincinnati, OH—August 24, 2018) Airway Therapeutics, LLC (“Airway”), a biotechnology company focused on developing new interventions for acute and chronic lung diseases, announces the appointment of Paul Kingma, MD, PhD to the position of Chief Medical Officer (“CMO”) as of August 1, 2018 in preparation for clinical development of AT-100, a recombinant form of human surfactant protein-D.

Dr. Kingma’s focus includes surfactant protein-D (“SP-D”) and its role in the pathogenesis of lung diseases, particularly in neonates; the development of the preterm lung; and bronchopulmonary dysplasia (“BPD”). Paul has been instrumental in supporting Airway with the development of the AT-100 formulation, analytical assays and animal experiments. He is also a member of Airway’s Scientific Advisory Board. Paul will assume his new role at Airway while maintaining some of his current roles at Cincinnati Children’s Hospital Medical Center.

Paul is Neonatal Director at the Cincinnati Fetal Center, Co-Director of the Cincinnati Bronchopulmonary Dysplasia Center, Attending Neonatologist at Cincinnati Children’s Hospital and Associate Professor of Pediatrics in the UC Department of Pediatrics. He has led numerous clinical and basic science studies, and has researched the biological activity and therapeutic potential of surfactant protein-D since 2001.

“Paul is the perfect match for Airway. He is a highly recognized expert in neonatology, BPD and SP-D, and he is a team player with great leadership skills,” said Marc Salzberg, CEO of Airway Therapeutics.

As CMO, Paul will lead the development of clinical studies with AT-100 and continue to help guide the current pre-clinical activities in preparation for clinical trials.

John Rice, Chairman of the Board of Airway, said, “We are excited to have Paul joining the company and preparing the clinical stage development of AT-100 with the Airway team.”

ABOUT AIRWAY THERAPEUTICS

Airway Therapeutics is a biotechnology company focused on developing new interventions for acute and chronic lung diseases in the most vulnerable of patients. Founded in 2011 as a spin-out of Cincinnati Children’s Hospital Medical Center, Airway Therapeutics has extensive expertise in protein development for applications in the lungs and pediatrics. Airway Therapeutics is currently developing an investigational product, AT-100, a recombinant form of human surfactant protein-D (rhSP-D), for the prevention of a serious lung condition called bronchopulmonary dysplasia (BPD) in preterm neonates.

CONTACT: Sandra Roberts roberts@airwaytheradev.wpengine.com

Filed Under: News

logo

Airway Therapeutics, Inc

1200 Johnson Ferry Rd, Suite 300
Marietta, GA 30068

513.770.9630

  • Privacy

Sitemap

  • Home
  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact
Copyright © 2015 Airway Therapeutics, Inc. All Rights Reserved.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.
Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
MENU
  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact